Comment from Andrea Sikora

Summary: The commenters, who are academics from the University of Colorado, Stanford, and Harvard, support the FDA's draft guidance for its "context-of-use" framework and risk matrix. However, they argue that the guidance should be strengthened by mandating disaggregated performance testing for subgroups, specifying lifecycle maintenance requirements, and including independent external validation and community involvement.